Simcere Lands Exclusive China Rights to Lynk's JAK1 Inhibitor Zemprocitinib
Simcere gains exclusive Greater China rights to Lynk's oral JAK1 inhibitor zemprocitinib for atopic dermatitis and other dermatology indications, weeks after the drug's NDA acceptance.